$3.58
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
Overview
52-week range
$1.60
$6.60
40% of range
Avg surprise (last 3)
-21.3%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
360%
EM ±82.4% · $4 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.35 | $-0.20 | -75.0% | +37.5% | -2.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.09 | $-0.82 | -32.9% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.56 | $1.00 | +44.0% | — | +4.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.12 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.79 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.97 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.36 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.29 | -$1.09 | +73.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-20M | — | $-13M | $-10M | $-11M | — | $-11M | $-10M |
| Net income | $-19M | — | $45M | $-10M | $-5M | — | $-10M | $-7M |
| EPS (diluted) | $-0.35 | — | $-0.21 | $-1.09 | $-0.56 | — | $-1.12 | $-0.79 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21M | $11M | $29M | $4M | $6M | $9M | $9M | $17M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $113M | $101M | $113M | $9M | $16M | $24M | $33M | $40M |
| Total assets | $248M | $173M | $183M | $30M | $38M | $44M | $54M | $62M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $21M | $21M | $18M | $18M | $17M | $18M | $17M | $16M |
| Total equity | $227M | $151M | $165M | $12M | $21M | $26M | $37M | $46M |